Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Hong Kong Stock Exchange](/topic/hong-kong-stock-exchange)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Pony AI has successfully passed the Hong Kong Stock Exchange listing hearing $PONY"  
[X Link](https://x.com/yangzhe1991/status/1979834285512446338) [@yangzhe1991](/creator/x/yangzhe1991) 2025-10-19T08:57Z XXX followers, XXX engagements


"$YGMZ this shytco do business within China only. WTF they need in American stock market. Why don't the list their shit on Hong Kong stock exchange because they know nobody was going to buy their trash"  
[X Link](https://x.com/Sonicconcept1/status/1979323465145683992) [@Sonicconcept1](/creator/x/Sonicconcept1) 2025-10-17T23:07Z XXX followers, XXX engagements


"While $IMAB's press release describes VIS-101 "to be acquired by Visara" ASK Pharma's Chinese listing announcement refers to it as a licensing agreement in licensed territories. According to ASK its controlling subsidiary AskGene Pharma has entered into a licensing agreement with Visara. AskGene Pharma grants Visara rights of its ASK G712 (VIS-101) within the licensed territories. The licensed regions include Greater China Singapore Thailand Malaysia Indonesia Vietnam South Korea and India. Visara will pay AskGene a one-time non-refundable upfront payment of $X million within XX business days"  
[X Link](https://x.com/chuminhua432/status/1979232899074580614) [@chuminhua432](/creator/x/chuminhua432) 2025-10-17T17:07Z 2906 followers, 1806 engagements


"$IMAB announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences. The Company also announced the pending acquisition of VIS-101 a novel bifunctional biologic targeting VEGF-A and ANG2. The pending acquisition will be made by a newly formed subsidiary Visara Inc. (Visara) a NewCo focused on developing ophthalmic therapeutics for serious eye disorders and is expected to be completed later this month. VIS-101 (also named lASKG712) is developed by ASK pharma the"  
[X Link](https://x.com/chuminhua432/status/1979230110109831631) [@chuminhua432](/creator/x/chuminhua432) 2025-10-17T16:56Z 2906 followers, 2438 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Hong Kong Stock Exchange

Top Social Posts

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"Pony AI has successfully passed the Hong Kong Stock Exchange listing hearing $PONY"
X Link @yangzhe1991 2025-10-19T08:57Z XXX followers, XXX engagements

"$YGMZ this shytco do business within China only. WTF they need in American stock market. Why don't the list their shit on Hong Kong stock exchange because they know nobody was going to buy their trash"
X Link @Sonicconcept1 2025-10-17T23:07Z XXX followers, XXX engagements

"While $IMAB's press release describes VIS-101 "to be acquired by Visara" ASK Pharma's Chinese listing announcement refers to it as a licensing agreement in licensed territories. According to ASK its controlling subsidiary AskGene Pharma has entered into a licensing agreement with Visara. AskGene Pharma grants Visara rights of its ASK G712 (VIS-101) within the licensed territories. The licensed regions include Greater China Singapore Thailand Malaysia Indonesia Vietnam South Korea and India. Visara will pay AskGene a one-time non-refundable upfront payment of $X million within XX business days"
X Link @chuminhua432 2025-10-17T17:07Z 2906 followers, 1806 engagements

"$IMAB announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences. The Company also announced the pending acquisition of VIS-101 a novel bifunctional biologic targeting VEGF-A and ANG2. The pending acquisition will be made by a newly formed subsidiary Visara Inc. (Visara) a NewCo focused on developing ophthalmic therapeutics for serious eye disorders and is expected to be completed later this month. VIS-101 (also named lASKG712) is developed by ASK pharma the"
X Link @chuminhua432 2025-10-17T16:56Z 2906 followers, 2438 engagements

Hong Kong Stock Exchange
/topic/hong-kong-stock-exchange/posts